Translational relevance
Colorectal cancer (CRC) is the third leading cause of cancer worldwide. Although current therapeutic regimens incorporate active chemotherapy and biological agents, patients eventually relapse without options for effective salvage therapy. Recent analysis of numerous clinical trials evaluating response rates of advanced CRC to epidermal growth factor receptor (EGFR) inhibitors demonstrated a correlation between activating mutations of the Kristen rat sarcoma viral oncogene homolog (KRAS) gene and resistance to these agents, thus identifying a large subset of patients in urgent need of alternative therapeutic approaches. In the present study, we utilized gene set enrichment analyses to support the rational combination of the MEK 1/2 inhibitor, selumetinib (AZD6244), and the histone deacetylase (HDAC) inhibitor, vorinostat (SAHA), against preclinical models of KRAS mutant CRC. Our data demonstrates that this combination exhibits potent, synergistic anti-tumor effects in, both in vitro and in vivo. These findings strongly support the clinical development of this rational combination in CRC patients with KRAS mutated tumors.
Introduction
Selumetinib (AZD6244; ARRY-142886) is a small molecule, orally available, non-competitive inhibitor of mitogen-activated protein kinase/extracellular signalregulated kinase 1/2 (MEK1/2) (1). The RAS/RAF/MEK/ERK kinase cascade occupies a central role in mediating signal transduction from extracellular growth factors, cytokines and proto-oncogenes. Alterations in the control of RAS/MAPK pathway, resulting in its constitutive activation, have a well-established role in oncogenesis and tumor growth, mostly related to uncontrolled cell proliferation and suppression of apoptosis (2) . The hyperactivation of this cascade is mediated through various mechanisms, including tyrosine kinase receptor over expression or mutations, or to KRAS or BRAF activating mutations. KRAS mutations are common in many different tumors, particularly in pancreatic (90%) and colon cancers (50%) (3, 4) . Although BRAF mutations are more common in melanoma (63%), papillary thyroid cancer (45%), and low grade ovarian cancers (50%), the BRAF V600E mutation has also been found in colorectal cancers that also exhibit defective DNA mismatch repair (5, 6) . The RAS/MAPK cascade is one of the major downstream signaling networks linking the epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), and vascular endothelial growth factor receptor-2 (VEGFR-2) pathways to nuclear proteins. The safety profile and tolerability of selumetinib has been evaluated in a two-part, multi-center, ascending dose, Phase I clinical study (7) . This trial demonstrated the tolerability of selumetinib, with the most common treatment-related toxicities being rash, diarrhea, nausea and fatigue.
Several phase II trials are ongoing to evaluate the activity of selumetinib, as single agent or in combination with chemotherapy in NSCLC, melanoma and colorectal cancer (8) (9) (10) Research.
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Histone deacetylation by HDACs is a post-translational modification of lysine residues in nucleosomal histone proteins that affects chromatin structure and, thereby, gene regulation (11) . Recently, HDAC activity has been shown to be up-regulated in cancer cells and it has been theorized that this results in repression of tumor suppressor gene products such as p53, making HDACs an attractive drug target (12, 13) . In cell culture models, HDAC inhibitors (HDACi) have been shown to decrease proliferation, and induce apoptosis or autophagy-related death of several cell lines (14) (15) (16) . Due to their relative specificity towards cancer cells, HDACi represent a new class of cancer treatment agents that are generally well tolerated. One such compound, vorinostat, (suberoylanilide hydroxamic acid, SAHA), has shown encouraging activity in early studies against several cancers including B-cell lymphoma (17) , colon cancer (18, 19) , non-small cell lung carcinoma (NSCLC) (20) , and head and neck cancer and is currently approved for the treatment of cutaneous T-cell lymphoma (21) . Several phase II studies have been conducted for breast (22) , colon and lung (23, 24) , head and neck (25) , and ovarian cancer patients (26) , however no consistent anti-tumor activity of vorinostat as single agent has been observed (11) . The prevailing view is that further investigations to evaluate the safety and activity of vorinostat as a combination partner are needed to better evaluate the potential of this agent in cancer treatment (27) . Several reports in the literature have demonstrated synergistic interaction between MEK and HDAC inhibitors.
Yu et al (28, 29) , demonstrated that combining HDAC with MEK inhibitors resulted in increased apoptosis, through the induction of oxidative damage and ROS generation (well known response markers for HDAC), as well as enhanced lethality in leukemia cells expressing the ABL/BCR mutation and resistance to imatinib. Based on these data, and our own transcriptional profiling and gene set enrichment analysis, we hypothesized that targeting the MEK pathway would inhibit signal transduction pathways involved in CRC tumor cell proliferation, survival and angiogenesis, and that this could be potentiated by combination with vorinostat (30) .
Furthermore, we focused these preclinical studies on CRC tumors expressing KRAS mutations, since they are associated with resistance to other signal transduction inhibitors, and represent a subtype of CRC that is in dire need of new therapeutic strategies. Finally, we aimed to establish sensitive in vivo end-points for MEK and HDAC inhibitors in a murine CRC xenograft model. LS174T (KRAS mut), LS1034 (KRAS mut), Colo205 (KRAS wt), and the RKO (KRAS wt). Cells were grown in RPMI medium supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids, 1% penicillin/streptomycin and maintained at 37 o C in an incubator under an atmosphere containing 5% CO 2 . The cells were routinely screened for the presence of mycoplasma (MycoAlert, Cambrex Bio Science, Baltimore, MD). Cytotoxic effects were determined using the sulforhodamine B (SRB) method as previously described (19) . Briefly, cells in logarithmic growth phase were transferred to 96 well flat bottom plates with lids. One hundred microliter of cell suspensions containing viable HCT116 (1,500 cells/well), HCT15 (2,000 cells/well), HCT8 (1,500 cells/well), GEO (2,000cells/well), SW837(1,500/well), HT29 (3,000cells/well), SW480 (2,500cells/well), SW620 (3,000cells/well), SW1417 (4,000cells/well), LoVo (5,000cells/well), LS513 (5,000cells/well), GEO (2,000cells/well), SW837(1,500/well), LS180 (3,000cells/well), LS174T (3,500cells/well), LS1034 (6,000cells/well), Colo205 Gene set enrichment analysis. Gene set analysis was performed using the GSEA BioCarta database as the gene set in this study (www.biocarta.com). One hundred and eighty eight gene sets passed the gene set size filter criteria (min = 10, max = 500).
In vitro evaluation of the combination effects of selumetinib and vorinostat. Synergy was determined for the KRAS-mut cell lines SW837, LS1034, HCT116, GEO, SW480
and SW620. These cell lines were selected because all of them contain KRAS mutations but exhibit divergent sensitivity to the single agents. To evaluate synergy cells were Care. Animals were housed 3-5 per cage and food and water were provided ad libitum.
All studies were conducted in accordance with the NIH Guidelines for the Care and Use
Research. (Figure 1 B) .
Effects of the Selumetinib and Vorinostat combination on proliferation of KRASmutant CRC cell lines in vitro.
To seek for a new active treatment for KRAS-mut CRC patient we studied the combination of selumetinib and vorinostat on GEO, HCT116, SW837, SW620 and LS1034. In an initial study, conduct on a panel of colorectal cancer cell lines to evaluate the activity of selumetinib and vorinostat as single agent, we observed that the SW837 and the SW480 were resistant to both selumetinib and vorinostat (R/R), the GEO were resistant to selumetinib and sensitive/intermediate for vorinostat (R/I-R), the LS1034 were sensitive to selumetinib and resistant to vorinostat (S/R), and the SW620 were sensitive to both drugs (S/S) as showed in Supplemental Data To assess the efficacy of selumetinib, vorinostat and the combination in a more physiological model, we next performed a 3 dimensional (3D) culture analysis with tumor spheroid formation in matrigel as the endpoint. As depicted in Figure 3 A-D, the SW620 S/S and SW480 R/R cells generated spheroids when growth in matrigel which were inhibited by both single agents and more strikingly, by the combination.
Interestingly, the SW480 R/R cells displayed a sensitive phenotype to selumetinib and vorinostat in 3D culture but a resistant phenotype in monolayer growth, suggesting that these agents require more intact tumor architecture to exert their full effects. Figure 4A) . By contrast, in the SW480, R/R cells, G1 arrest was induced by treatment with selumetinib which was maintained in the combination ( Figure 4B) . Next, we evaluated the ability of selumetinib, vorinostat, or the combination to induce apoptosis in SW620 and SW480 cells after 24 hours of exposure to these agents using a caspase 3/7 activity assay. While phospholipids.To assess the effects of selumetinib in combination with vorinostat on glucose uptake, 18 FDG-PET was performed on mice bearing SW620 tumors at baseline, before starting treatment, after four days of treatment to evaluate early drug effects and after 21 days of treatment with either vehicle, selumetinib, vorinostat, or the combination.
No significant decreases in glucose uptake were observed in either study group when compared to untreated controls after three days of treatment (data not shown), while a trend of decrease in glucose uptake was observed day 21 in the selumetinib and combo group compared with vorinostat ( Figure 5 C, D *p<0.05).
Discussion
Recent efforts in cancer therapeutics have focused on the development of targeted therapies directed towards specific molecules related to cancer cell biology in order to achieve a more specific and effective treatment, and at the same time, avoid some of the systemic toxicities associated with chemotherapy (51, 52) . To optimize this therapeutic approach, patient selection for clinical trials has become of critical importance (53-56).
For example, recent studies have shown a correlation between CRC tumors with activating KRAS mutations and resistance to EGFR-targeted therapies. Therefore, there is an emerging need for alternative therapeutic approaches for this patient population (5, 56, 57) . In the present study, we utilized in vitro and in vivo models of CRC to evaluate the efficacy of selumetinib in combination with vorinostat as a potential therapeutic strategy for the treatment of CRC patients expressing mutant KRAS. Our data demonstrated that this combination exerts potent anti-tumor effects on in vitro models of CRC including synergistic inhibition of cell proliferation, G1 cell cycle arrest, induction of apoptosis, and spheroid formation in 3D culture. Interestingly, this combination
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inhibited CRC cell migration, which suggests that this treatment not only inhibits tumor growth, but may play a role in the metastatic process as well. In vivo studies using KRAS mutant CRC xenograft models in nude mice confirmed the anti-tumor effects of the combination of selumetinib and vorinostat, although synergy was not observed, likely due to the single-agent effects of selumetinib.
In our initial studies, we evaluated selumetinib and vorinostat as single agents To further evaluate the synergistic effects of this combination, we chose to focus on several KRAS mutant CRC cell lines. Our results showed that the combination of selumetinib and vorinostat resulted in a synergistic antiproliferative effects in all cell lines studied. Mechanistically, our results suggest that this antiprolifterative effect of combination of selumetinib and vorinostat is mediated by an increase in apoptotic cell death as measured by caspase 3/7 activity, cleaved PARP and perhaps increased acetylated histone H3 levels. This is in accordance with previous reports demonstrating that MEK inhibition was synergistic with HDAC inhibitor through the induction of cell death via apoptosis (29) . We also evaluated the effects of the combination on cell cycle distribution and apoptotic events. It has been previously reported that vorinostat increases the expression of cyclin-independent kinases such as p21 CIP/WAF1 in bladder cancer, and p27 KIP1 in gliomas, and induces G2/M cell cycle arrest in CRC cell lines, while selumetinib induced G1 cell cycle arrest and induction of apoptosis in a CRC xenograft model (1, 19, 60) . In our study, we observed a G1 cell cycle arrest in the SW620 S/S cell line after each single agent treatment that was significantly increased after exposure to the combination. In the SW480 R/R cell line, vorinostat showed no effects on cell cycle distribution, while single-agent selumetinib and combination treatment resulted in a G1
arrest, suggesting that the combination effects were mediated by selumetinib.
Because cell proliferation is only one phenotypic endpoint of malignant behavior, we used other in vitro models such as a modified Boyden chamber and three-dimensional culture (3D) and found that the combination of these agents resulted in significant decreases in cell motility and spheroid formation, respectively. As MEK is a downstream effector of the EGFR, VEGFR and IGF-1R signaling pathways, we hypothesized that In our in vivo studies of both SW620 (S/S) and SW480 (R/R) cell line xenografts, combination treatment demonstrated significant tumor growth inhibition compared to untreated controls or vorinostat, but not to single-agent selumetinib. As would be expected from the 3D results, the SW480 xenograft was sensitive to selumetinib in vivo, which we hypothesize could be related to MEK-dependent effects on the tumor 
